|
|
Article: Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc. and Findings from Cervarix, GSK's Cervical Cancer Candidate Vaccine, Suggests Vaccination Could Reduce Cervical Cancers by up to 80%.
- Article from:
- M2 Presswire
- Article date:
- October 31, 2006
CopyrightCOPYRIGHT 2006 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-31 October 2006-U.S. Equity News: Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc. and Findings from Cervarix, GSK's Cervical Cancer Candidate Vaccine, Suggests Vaccination Could Reduce Cervical Cancers by up to 80%(C)1994-2006 M2 COMMUNICATIONS LTD
RDATE:31102006
City of Industry, CA - October 31, 2006 - Pharmaceuticals Instruments industry alert provided by U.S. Equity News. Merck & Co., Inc. (NYSE: MRK), one of the world's leading research-based pharmaceutical companies, and Sirna Therapeutics, Inc. (NASDAQ: RNAI), a publicly held biotechnology company and a leader in developing a new class of medicines based on RNA interference ...
Related newspaper, magazine, and journal articles:
|
|
Article: National Cervical Cancer Coalition to Host First ...
U.S. Newswire;
August 27, 2007 ;
700+ words
... ... Rachel Biety of the National Cervical Cancer Coalition, +1-818 ... com, for the National Cervical Cancer Coalition LOS ANGELES ... USNewswire/ -- The National Cervical Cancer Coalition (NCCC) takes ...
|
|